[go: up one dir, main page]

AR125320A2 - Compuesto cristalino, método de preparación y composición que lo comprende - Google Patents

Compuesto cristalino, método de preparación y composición que lo comprende

Info

Publication number
AR125320A2
AR125320A2 ARP220100894A ARP220100894A AR125320A2 AR 125320 A2 AR125320 A2 AR 125320A2 AR P220100894 A ARP220100894 A AR P220100894A AR P220100894 A ARP220100894 A AR P220100894A AR 125320 A2 AR125320 A2 AR 125320A2
Authority
AR
Argentina
Prior art keywords
preparation
crystalline compound
composition including
crystalline
compositions
Prior art date
Application number
ARP220100894A
Other languages
English (en)
Inventor
Paul Steven Watson
Bret Berner
John Gregory Reid
Jian Wang
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of AR125320A2 publication Critical patent/AR125320A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Un compuesto cristalino que tiene la fórmula (1). También se divulgan métodos de elaboración y composiciones que lo comprenden.
ARP220100894A 2016-08-23 2022-04-08 Compuesto cristalino, método de preparación y composición que lo comprende AR125320A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662378582P 2016-08-23 2016-08-23

Publications (1)

Publication Number Publication Date
AR125320A2 true AR125320A2 (es) 2023-07-05

Family

ID=59772778

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP170102330A AR109393A1 (es) 2016-08-23 2017-08-23 Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
ARP220100895A AR125321A2 (es) 2016-08-23 2022-04-08 Compuesto cristalino, método de preparación y composición que lo comprende
ARP220100894A AR125320A2 (es) 2016-08-23 2022-04-08 Compuesto cristalino, método de preparación y composición que lo comprende

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP170102330A AR109393A1 (es) 2016-08-23 2017-08-23 Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
ARP220100895A AR125321A2 (es) 2016-08-23 2022-04-08 Compuesto cristalino, método de preparación y composición que lo comprende

Country Status (24)

Country Link
US (4) US11236121B2 (es)
EP (2) EP3504189A1 (es)
JP (3) JP2019524853A (es)
KR (2) KR20190040043A (es)
CN (4) CN115974955A (es)
AR (3) AR109393A1 (es)
AU (3) AU2017315682B2 (es)
BR (1) BR112019003637A2 (es)
CA (1) CA3034262A1 (es)
CL (2) CL2019000477A1 (es)
CO (1) CO2019002596A2 (es)
EA (1) EA201990565A1 (es)
EC (1) ECSP19020141A (es)
IL (2) IL315950A (es)
JO (1) JOP20190022B1 (es)
MA (1) MA46042A (es)
MX (2) MX393240B (es)
MY (1) MY200479A (es)
PE (2) PE20190915A1 (es)
PH (1) PH12019500375A1 (es)
SG (1) SG11201901445TA (es)
TW (3) TWI904593B (es)
WO (1) WO2018039378A1 (es)
ZA (1) ZA201901051B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2766380B1 (en) 2011-10-14 2019-04-24 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
RU2019126333A (ru) 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
TW202426002A (zh) 2014-10-16 2024-07-01 美商賽吉醫療公司 用於治療中樞神經系統(cns)病症之組合物及方法
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
CN116162121A (zh) 2016-07-11 2023-05-26 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
EP3481844B1 (en) 2016-07-11 2024-04-17 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CN115974955A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
IL303250A (en) * 2017-09-07 2023-07-01 Sage Therapeutics Inc Neuroactive steroids and their methods of use
WO2019055764A1 (en) * 2017-09-14 2019-03-21 Sage Therapeutics, Inc. C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
EP3806863A1 (en) * 2018-06-12 2021-04-21 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
MX2021006618A (es) 2018-12-05 2021-09-23 Sage Therapeutics Inc Esteroides neuroactivos y sus metodos de uso.
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
WO2020155057A1 (zh) * 2019-01-31 2020-08-06 深圳仁泰医药科技有限公司 γ-氨基丁酸调节剂的晶型X及其制备方法和应用
WO2020242772A1 (en) 2019-05-28 2020-12-03 Teva Czech Industries S.R.O Solid state forms of sage-217 and processes for preparation thereof
PH12021553005A1 (en) 2019-05-31 2023-08-14 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CN118027131A (zh) * 2019-08-07 2024-05-14 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
IL296645A (en) 2020-03-25 2022-11-01 Sage Therapeutics Inc Use of agents for treatment of respiratory conditions
BR112023000990A2 (pt) * 2020-07-20 2023-03-28 Sage Therapeutics Inc Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas
WO2022072620A1 (en) * 2020-10-01 2022-04-07 Eliem Therapeutics (UK) Ltd Methods of treating fibromyalgia with neuroactive steroids
WO2022165017A1 (en) 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
BR112023018607A2 (pt) * 2021-03-17 2023-10-24 Sage Therapeutics Inc Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior
MX2023012728A (es) 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.
KR20240006026A (ko) 2021-04-29 2024-01-12 세이지 테라퓨틱스, 인크. 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
PE20240780A1 (es) 2021-07-28 2024-04-17 Sage Therapeutics Inc Formas cristalinas de un esteroide neuroactivo
KR20240148425A (ko) 2022-02-16 2024-10-11 세이지 테라퓨틱스, 인크. Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20250177418A1 (en) 2022-02-28 2025-06-05 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
ES2356306T3 (es) 2002-02-08 2011-04-06 Ono Pharmaceutical Co., Ltd. Compuestos y fármacos derivados de piperidina que contienen los compuestos como principio activo.
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2766380B1 (en) 2011-10-14 2019-04-24 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
WO2014058736A1 (en) 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
SG11201504848QA (en) 2012-12-18 2015-07-30 Univ Washington Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
RU2019126333A (ru) 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
EP4144746A1 (en) 2014-05-29 2023-03-08 Sage Therapeutics, Inc. Neuroactive steroids, compositions and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
TW202426002A (zh) 2014-10-16 2024-07-01 美商賽吉醫療公司 用於治療中樞神經系統(cns)病症之組合物及方法
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
DK3250210T3 (da) 2015-01-26 2021-03-08 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
JP2018526423A (ja) 2015-09-08 2018-09-13 ビューポイント セラピューティクス， インコーポレイテッド 眼科疾患を処置するための化合物および製剤
CN108135838A (zh) 2015-10-16 2018-06-08 马瑞纳斯制药公司 包含纳米粒的可注射神经类固醇制剂
US20200306262A1 (en) 2015-11-20 2020-10-01 Sage Therapeutics, Inc. Compounds and methods of their use
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
EP3481844B1 (en) 2016-07-11 2024-04-17 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CN116162121A (zh) 2016-07-11 2023-05-26 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
CN115974955A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
JP7196157B2 (ja) 2017-08-31 2022-12-26 武田薬品工業株式会社 Ｃｎｓ状態の治療
IL303250A (en) 2017-09-07 2023-07-01 Sage Therapeutics Inc Neuroactive steroids and their methods of use
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
WO2019055764A1 (en) 2017-09-14 2019-03-21 Sage Therapeutics, Inc. C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME
WO2019094724A1 (en) 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
MA51315A (fr) 2017-12-22 2020-10-28 Sage Therapeutics Inc Compositions et méthodes permettant de traiter des troubles du snc
MA51316A (fr) 2017-12-22 2020-10-28 Sage Therapeutics Inc Compositions et méthodes permettant de traiter les troubles du snc
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
EP3806863A1 (en) 2018-06-12 2021-04-21 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
EP4321519A3 (en) 2018-10-12 2024-05-01 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
EP4606812A3 (en) 2018-10-19 2025-10-15 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
MX2021006618A (es) 2018-12-05 2021-09-23 Sage Therapeutics Inc Esteroides neuroactivos y sus metodos de uso.
US20220372067A1 (en) 2018-12-21 2022-11-24 Sage Therapeutics, Inc. 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
TW202523658A (zh) 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
PH12021553005A1 (en) 2019-05-31 2023-08-14 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
MX2021015848A (es) 2019-06-27 2022-04-18 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del snc.
CA3143509A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI896548B (zh) 2019-06-27 2025-09-11 美商賽吉醫療公司 用於治療cns病症之組合物及方法
CN114761019A (zh) 2019-12-05 2022-07-15 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
CN115551874A (zh) 2020-03-18 2022-12-30 萨奇治疗股份有限公司 神经活性类固醇及其使用方法
IL296645A (en) 2020-03-25 2022-11-01 Sage Therapeutics Inc Use of agents for treatment of respiratory conditions
IL299176A (en) 2020-06-24 2023-02-01 Sage Therapeutics Inc Neuroactive steroids converted to 3.alpha.-hydroxy, 17.beta.-C-(O)-N-aryl and their compounds
BR112023000990A2 (pt) 2020-07-20 2023-03-28 Sage Therapeutics Inc Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas
IL303101A (en) 2020-11-25 2023-07-01 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2022165017A1 (en) 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
BR112023018607A2 (pt) 2021-03-17 2023-10-24 Sage Therapeutics Inc Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior
IL307516A (en) 2021-04-12 2023-12-01 Sage Therapeutics Inc Tremor treatment
MX2023012728A (es) 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.
KR20240006026A (ko) 2021-04-29 2024-01-12 세이지 테라퓨틱스, 인크. 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20240148425A (ko) 2022-02-16 2024-10-11 세이지 테라퓨틱스, 인크. Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20250177418A1 (en) 2022-02-28 2025-06-05 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Also Published As

Publication number Publication date
US20250304615A1 (en) 2025-10-02
JOP20190022A1 (ar) 2019-02-18
AU2022200811B2 (en) 2023-12-21
US20220169674A1 (en) 2022-06-02
KR20230079470A (ko) 2023-06-07
AU2022200811A1 (en) 2022-02-24
TWI808945B (zh) 2023-07-21
MA46042A (fr) 2019-07-03
ECSP19020141A (es) 2019-04-30
JOP20190022B1 (ar) 2023-03-28
AU2024200732A1 (en) 2024-02-22
AR109393A1 (es) 2018-11-28
US11236121B2 (en) 2022-02-01
TWI904593B (zh) 2025-11-11
SG11201901445TA (en) 2019-03-28
US20190177359A1 (en) 2019-06-13
CA3034262A1 (en) 2018-03-01
TW201808982A (zh) 2018-03-16
CN115974955A (zh) 2023-04-18
JP2019524853A (ja) 2019-09-05
MX2022007432A (es) 2022-07-19
CO2019002596A2 (es) 2019-03-29
CN115974956A (zh) 2023-04-18
TWI854445B (zh) 2024-09-01
TW202342059A (zh) 2023-11-01
NZ750729A (en) 2025-05-30
ZA201901051B (en) 2020-12-23
CL2019000477A1 (es) 2019-06-21
MY200479A (en) 2023-12-28
JP2024097878A (ja) 2024-07-19
WO2018039378A1 (en) 2018-03-01
US20230399357A1 (en) 2023-12-14
EA201990565A1 (ru) 2019-07-31
JP2023002846A (ja) 2023-01-10
AR125321A2 (es) 2023-07-05
AU2017315682A2 (en) 2019-04-18
US12358942B2 (en) 2025-07-15
AU2022200811B9 (en) 2024-01-04
EP3504189A1 (en) 2019-07-03
AU2017315682A1 (en) 2019-03-07
AU2017315682B2 (en) 2021-11-11
BR112019003637A2 (pt) 2019-08-06
PH12019500375A1 (en) 2019-06-17
KR20190040043A (ko) 2019-04-16
CN110088091A (zh) 2019-08-02
MX2019002193A (es) 2019-10-07
US11884696B2 (en) 2024-01-30
CN115974954A (zh) 2023-04-18
MX393240B (es) 2025-03-24
TW202500158A (zh) 2025-01-01
PE20190915A1 (es) 2019-06-26
IL315950A (en) 2024-11-01
IL302480A (en) 2023-06-01
NZ791594A (en) 2025-08-29
PE20241580A1 (es) 2024-08-01
CL2019003610A1 (es) 2020-05-22
EP3981763A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
AR125320A2 (es) Compuesto cristalino, método de preparación y composición que lo comprende
CR20160419A (es) Nuevos compuestos biciclicos
PL3577110T3 (pl) Związki podstawione 8-oksetan-3-ylo-3,8-diazabicyklo[3.2.1]oktan-3-ylem jako inhibitory hiv
EA201992177A1 (ru) Композиции на основе нирапариба
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
MX377277B (es) Derivados de fenoximetilo.
MX2019009861A (es) Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.
UA120058C2 (uk) Пестицидні композиції
WO2018006074A3 (en) Compounds and methods for modulating rna function
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
EA201890752A1 (ru) Способ получения противогрибковых соединений
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EA201790064A1 (ru) Пестицидные композиции
ZA202309446B (en) Rapamycin analogs and uses thereof
EA201792067A1 (ru) Противогрибковые соединения и способы получения
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
MY192425A (en) Polymorphs
MX367669B (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos.
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.